Associate Professor of Medicine, Johns Hopkins University School of Medicine; Assistant Professor
Rheumatology
Dr. Laura Hummers, MD
|
|
Give Review
Laura Hummers, MD practices Rheumatology. She went to University of Rochester School of Medicine and Dentistry. She received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Laura Hummers, MD is also published. She has 58 publications published. The lastest publication: "Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.' She accepts Medicare payments and is registered with Medicare.gov.
Publications
- Severity of muscle weakness independently associates with disability as measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) in Scleroderma.
- Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated Scleroderma.
- Antinuclear antibody-negative Systemic sclerosis.
- Intravenous Immunoglobulin May Be an Effective Therapy for Refractory, Active Diffuse Cutaneous Systemic Sclerosis.
- Development of pulmonary hypertension in a high-risk population with Systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Sclerod...
- International consensus criteria for the diagnosis of Raynaud's phenomenon.
- Immunochip analysis identifies multiple susceptibility Loci for Systemic sclerosis.
- Connective tissue Disease related interstitial lung Diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical tr...
- Survival and predictors of mortality in Systemic sclerosis associated pulmonary arterial hypertension: Outcomes from the PHAROS registry.
- Changes in estimated right ventricular systolic pressure predict mortality and pulmonary hypertension in a cohort of Scleroderma patients.
- Race and association with Disease manifestations and mortality in scleroderma: a 20-year experience at the johns hopkins scleroderma center and review of the literature.
- Systemic sclerosis-challenges for clinical practice.
- Repeated treatment with high dose cyclophosphamide for severe autoimmune Diseases.
- A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud...
- Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
- Erythroid-Specific Transcriptional Changes in PBMCs from Pulmonary Hypertension Patients.
- Pulmonary hypertension and interstitial lung Disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.
- A case-control study of the pathology of oesophageal Disease in systemic sclerosis (scleroderma).
- Abnormal exhaled ethane concentrations in Scleroderma.
- Distinct recognition of antibodies to centromere proteins in primary Sjogren''s Syndrome compared with limited scleroderma.
- High-dose cyclophosphamide without stem cell rescue in Scleroderma.
- Biomarkers of vascular Disease in scleroderma.
- The "tank top sign": a unique pattern of skin fibrosis seen in pansclerotic morphea.
- Disproportionate elevation of N-terminal pro-brain natriuretic peptide in Scleroderma-related pulmonary hypertension.
- Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension.
- Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies.
- Management of Raynaud's phenomenon and digital ischemic lesions in Scleroderma.
- Increased microchimeric CD4+ T lymphocytes in peripheral blood from women with Systemic sclerosis.
- Tricuspid annular plane systolic excursion is a robust outcome measure in Systemic sclerosis-associated pulmonary arterial hypertension.
- Identification of novel genetic markers associated with clinical phenotypes of Systemic sclerosis through a genome-wide association strategy.
- Late-age onset Systemic sclerosis.
- Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung Disease.
- Systemic sclerosis-related pulmonary hypertension associated with interstitial lung Disease: impact of pulmonary arterial hypertension therapies.
- Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous Systemic sclerosis.
- Vascular Disease in systemic sclerosis.
- Cardiac complications of Systemic sclerosis: recent progress in diagnosis.
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.
- Close temporal relationship between onset of cancer and Scleroderma in patients with RNA polymerase I/III antibodies.
- The current state of biomarkers in Systemic sclerosis.
- Genome-wide association study of Systemic sclerosis identifies CD247 as a new susceptibility locus.
- Hemodynamic predictors of survival in Scleroderma-related pulmonary arterial hypertension.
- Telangiectases in Scleroderma: a potential clinical marker of pulmonary arterial hypertension.
- Regulation of pulmonary inflammation and fibrosis through expression of integrins alphaVbeta3 and alphaVbeta5 on pulmonary T lymphocytes.
- Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and Systemic sclerosis patient sera.
- Abnormalities in the regulators of angiogenesis in patients with Scleroderma.
- Survival in pulmonary hypertension associated with the scleroderma spectrum of Diseases: impact of interstitial lung Disease.
- The importance of recognizing Scleroderma-type disorders in clinical practice.
- Identification of candidate genes in Scleroderma-related pulmonary arterial hypertension.
- Scleroderma-like fibrosing disorders.
- Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG).
- Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung Disease.
- Antiangiogenic plasma activity in patients with Systemic sclerosis.
- Efficacy and safety of etanercept in the treatment of scleroderma-associated joint Disease.
- Clinical differences between idiopathic and Scleroderma-related pulmonary hypertension.
- Microvascular damage in Systemic sclerosis: detection and monitoring with biomarkers.
- Paclitaxel modulates TGFbeta signaling in Scleroderma skin grafts in immunodeficient mice.
- Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.
Schools
University Of Rochester School Of Medicine and Dentistry
Jefferson University Hospital
Johns Hopkins University Hospital
Procedures Preformed
- Joint Drainage
Conditions Treated
- Arthritis
- Dermatomyositis
- Fibromyalgia
- Gout
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
Johns Hopkins University -
Thomas Jefferson University -
University of Rochester School of Medicine and Dentistry
Hospital
-
Johns Hopkins Bayview Medical Center -
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1104879527 | |
| NPPES Provider LastName | HUMMERS | |
| NPPES Provider FirstName | LAURA | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 513.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 34.0 | |
| Percent Opioid Claims | 6.63 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1104879527 |
| Last Name Of The Provider | HUMMERS |
| First Name Of The Provider | LAURA |
| View All |
Similar Doctors
|
|
Dr. Peter A. Holt, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bernadette C. Siaton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohammad E. Oreizi-Esfahani, MD |
|
|
Dr. Juwaria F. Waheed, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julius Birnbaum, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca L. Manno, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie J. Paik, MD |
|
|
Dr. Robert L. Marcus, MD |
|
|
Dr. Amit Golding, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brendan A. Antiochos, MD
This Doctor is OpenDoctor Recommended.
|